Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
pharmacology, toxicology and pharmaceutics
Pilot study to evaluate the safety and therapeutic efficacy of topical oxifulvic acid in atopic volunteers
Drug Development Research, Volume 57, No. 1, Year 2002
Notification
URL copied to clipboard!
Description
The study objectives were to establish first the safety and second the therapeutic efficacy of topically applied oxifulvic acid compared to 1% hydrocortisone and placebo creams. Oxifulvic acid has established antiinflammatory properties in vitro. It also inhibits elicited ear inflammation in mice at concentrations of 4.5 and 9%. In this double-blind cross-over study, 23 healthy volunteers allergic to grass or house dust mite allergen were recruited and included after signing informed consent. During the initial run-in period all volunteers were randomized to apply either 4.5 or 9% oxifulvic acid for 2 weeks on the volare aspect of one forearm (100 mm diameter) and rechallenged 21 days later to establish sensitization. Thereafter, volunteers were randomized to either placebo. 1% hydrocortisone, 4.5 or 9% oxifulvic acid creams. Creams were applied under occlusions 1 h prior to intradermal allergen challenge and every 8 h thereafter for 3 days (21-day intervals). The surface areas of the immediate and late phase skin reactions were calculated. Liver and kidney function tests as well as full blood counts were done at screening and thereafter weekly for the first 2 weeks and then at each follow-up visit. Topically applied oxifulvic acid had no significant effect on any of the safety parameters and also did not induce sensitization when applied on the skin. Oxifulvic acid (4.5%) caused inhibition of the elicited inflammatory reaction at 15 min and differed significantly from the 9% cream at 24 h. These changes were similar to that caused by hydrocortisone. No other significant changes were detected. © 2002 Wiley-Liss, Inc.
Authors & Co-Authors
Snyman, Jacques Renè
South Africa, Pretoria
Faculty of Health Sciences
Dekker, Johannes
South Africa, Pretoria
Enerkom Pty Ltd.
Malfeld, Susan C.K.
South Africa, Pretoria
Faculty of Health Sciences
Van Rensburg, Constance Elizabeth Jansen
South Africa, Pretoria
Faculty of Health Sciences
Statistics
Citations: 20
Authors: 4
Affiliations: 2
Identifiers
Doi:
10.1002/ddr.10116
ISSN:
02724391
Research Areas
Disability
Study Design
Cohort Study